The efficacy and safety of irinotecan cisplatin and mitomycin chemotherapy in sunitinib pre-treated metastatic clear cell renal cancer

Figures & data

Table 1 Patient characteristics and outcome

Risk at time of sunitinib therapy (Motzer et al 2004)	Initial response to sunitinib therapy	TTP during sunitinib therapy	Risk at time of IPM (Motzer et al 2004)	Response to IPM after 2 cycles	Grade 3 or 4 toxicity on IPM	TTP on IPM (months)	Overall survival from time of starting IPM (months)	Overall survival from time of diagnosis of metastatic renal cancer
int	PR	14.3	int	PD	–	1,4	4.2	31
Poor	PD	2.8	poor	PD	–	0.5	0.5	6.1
Int	PD	4.8	poor	PD	Dia	0.9	2.1	9.2
Int	SD	8.3	poor	PD	–	1.8	3.0	27.4
Good	PR	12.2	poor	PD	Dia, lethergy	1.4	1.6	33.0
Poor	SD	7.2	int	PD	Lethargy	2.8	6.2	16.9
int	PR	6.2	poor	PR	–	11.0PF	11.0A	34.3A
Poor	SD	2.1	poor	SD	Neut. Sepsis. Lethargy	2.3T	7.8	18.1
int	SD	10.5	poor	PD	–	0.9	5	20.5
poor	SD	2.7	poor	PD	–	1.8	5.3	24.4
Int	PR	11.3	int	PD	–	1.4	2.1	15.6

A Notes: Alive

PF Progression free

T Stopped due to toxicity.

Abbreviations: TTP, time to progression; Int, intermediate; Neut, neutropenic; Dia, diarrhea.

Figure 1 Kaplan Meier curve showing overall survival associated with IPM chemotherapy after progression on sunitinib therapy.

Figure 2 Kaplan Meier curve showing progression-free survival with IPM chemotherapy.

MotzerRJBacikJSchwartzLH2004Prognostic factors for survival in previously treated patients with metastatic renal cell carcinomaJ Clin Oncol224546314752067

 PubMed Web of Science ®Google Scholar